DDInter1638 DDInter899
Samarium Sm 153 lexidronam is a radioactive medication used to treat pain caused by cancer that has spread to the bone. It is a radiopharmaceutical. Radiopharmaceuticals are radioactive agents that may be used to diagnose some diseases by studying the function of the body's organs or to treat certain diseases.Samarium Sm 153 lexidronam is used to help relieve the bone pain that may occur with certain kinds of cancer. The radioactive samarium is taken up in the bone cancer area and gives off radiation that helps provide relief of pain.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Samarium (153Sm) lexidronam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Foscarnet
Samarium (153Sm) lexidronam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ocrelizumab
Samarium (153Sm) lexidronam {u} may lead to a major life threatening interaction when taken with {v} Altretamine
Samarium (153Sm) lexidronam {u} may lead to a major life threatening interaction when taken with {v} Polatuzumab vedotin
Samarium (153Sm) lexidronam may cause a moderate interaction that could exacerbate diseases when taken with Foscarnet
Samarium (153Sm) lexidronam may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Samarium (153Sm) lexidronam may lead to a major life threatening interaction when taken with Altretamine
Samarium (153Sm) lexidronam may lead to a major life threatening interaction when taken with Polatuzumab vedotin